P218
/ Medicines for Malaria Venture
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 31, 2021
Decreased susceptibility to dihydrofolate reductase inhibitors associated with genetic polymorphisms in Ugandan Plasmodium falciparum isolates.
(PubMed, J Infect Dis)
- "Resistance-mediating PfDHFR mutations were common in Ugandan isolates, but P218 retained excellent activity against mutant parasites."
Journal • Infectious Disease • Malaria • DHFR
June 03, 2021
Concentration-QT Modeling of the Novel DHFR Inhibitor P218 in Healthy Male Volunteers.
(PubMed, Br J Clin Pharmacol)
- "Oral administration of P218 up to 1000 mg does not prolong QTcF and does not significantly change QRS or PR intervals, suggesting low risk for drug-induced proarrhythmia."
Clinical • Journal • Atrial Fibrillation • Cardiovascular • Infectious Disease • Malaria • DHFR
1 to 2
Of
2
Go to page
1